199 related articles for article (PubMed ID: 11423263)
21. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy.
Grulich AE; Li Y; McDonald AM; Correll PK; Law MG; Kaldor JM
AIDS; 2001 Mar; 15(5):629-33. PubMed ID: 11317001
[TBL] [Abstract][Full Text] [Related]
22. AIDS-related cancers in the era of highly active antiretroviral therapy.
Biggar RJ
Oncology (Williston Park); 2001 Apr; 15(4):439-48; discussion 448-9. PubMed ID: 11346932
[TBL] [Abstract][Full Text] [Related]
23. Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy.
Bernstein WB; Little RF; Wilson WH; Yarchoan R
Int J Hematol; 2006 Jul; 84(1):3-11. PubMed ID: 16867895
[TBL] [Abstract][Full Text] [Related]
24. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE
HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
[TBL] [Abstract][Full Text] [Related]
26. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
[TBL] [Abstract][Full Text] [Related]
27. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
Wolf T; Brodt HR; Fichtlscherer S; Mantzsch K; Hoelzer D; Helm EB; Mitrou PS; Chow KU
Leuk Lymphoma; 2005 Feb; 46(2):207-15. PubMed ID: 15621803
[TBL] [Abstract][Full Text] [Related]
28. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.
Vilchez RA; Finch CJ; Jorgensen JL; Butel JS
Medicine (Baltimore); 2003 Mar; 82(2):77-81. PubMed ID: 12640183
[TBL] [Abstract][Full Text] [Related]
29. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group.
Jones JL; Hanson DL; Dworkin MS; Ward JW; Jaffe HW
J Acquir Immune Defic Syndr; 1999 Aug; 21 Suppl 1():S11-7. PubMed ID: 10430212
[TBL] [Abstract][Full Text] [Related]
30. Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management.
Yarchoan R; Tosato G; Little RF
Nat Clin Pract Oncol; 2005 Aug; 2(8):406-15; quiz 423. PubMed ID: 16130937
[TBL] [Abstract][Full Text] [Related]
31. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review.
Cobucci RN; Lima PH; de Souza PC; Costa VV; Cornetta Mda C; Fernandes JV; Gonçalves AK
J Infect Public Health; 2015; 8(1):1-10. PubMed ID: 25294086
[TBL] [Abstract][Full Text] [Related]
32. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS.
Diamond C; Taylor TH; Im T; Anton-Culver H
Leuk Lymphoma; 2006 Sep; 47(9):1822-9. PubMed ID: 17064995
[TBL] [Abstract][Full Text] [Related]
33. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.
Stebbing J; Gazzard B; Mandalia S; Teague A; Waterston A; Marvin V; Nelson M; Bower M
J Clin Oncol; 2004 Jun; 22(11):2177-83. PubMed ID: 15169806
[TBL] [Abstract][Full Text] [Related]
34. Less cancer--or more--with HAART? Or, reflections on a late opus.
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Jun; 4(6):12-22. PubMed ID: 11365531
[TBL] [Abstract][Full Text] [Related]
35. Current approaches to the treatment of HIV-related Kaposi's sarcoma and lymphoma by chemotherapy.
Stewart JS
AIDS; 1990; 4 Suppl 1():S217-21. PubMed ID: 2152571
[No Abstract] [Full Text] [Related]
36. The effects of HAART on AIDS-related Kaposi's sarcoma and non-Hodgkin's lymphoma.
Clayton G; Omasta-Martin A; Bower M
J HIV Ther; 2006 Sep; 11(3):51-3. PubMed ID: 17580498
[No Abstract] [Full Text] [Related]
37. Clinical aspects and management of AIDS-related lymphoma.
Sparano JA
Eur J Cancer; 2001 Jul; 37(10):1296-305. PubMed ID: 11423261
[TBL] [Abstract][Full Text] [Related]
38. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
39. The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma.
Casper C; Wald A
Curr Top Microbiol Immunol; 2007; 312():289-307. PubMed ID: 17089802
[TBL] [Abstract][Full Text] [Related]
40. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
